Advanced search
Publication Cover
Expert Review of Vaccines Volume 3, 2004 - Issue sup1
Submit an article Journal homepage
19
Views
30
CrossRef citations to date
0
Altmetric
Review

A call for replicating vector prime-protein boost strategies in HIV vaccine design

Nina V Malkevitch Section on Immune Biology of Retroviral Infection, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 20892 5065, USA. [email protected]
&
Marjorie Robert-Guroff Section on Immune Biology of Retroviral Infection, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 20892 5065, USA. [email protected]
Pages S105-S117 | Published online: 09 Jan 2014

References

  • Robinson HL. New hope for an AIDS vaccine. Nature Rev Immunol 2,239–250 (2002).
  • Kwong PD, Wyatt R, Robinson J, Sweet RVV, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393,648–659 (1998).
  • Wyatt R, Kwong PD, Desjardins E etal. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393, 705–711 (1998).
  • Wei X, Decker JM, Wang S et al Antibody neutralization and escape by HIV-1. Nature 422,307–312 (2003).
  • •Describes the rapid escape from neutralizing antibodies which occurs following HIV infection of people.
  • Nishimura Y, Igarashi T, Haigwood NL et al. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implication for HIV-1 vaccine development. Proc. Natl Acad. Sci. USA 100,15131–15136 (2003).
  • ••Illustrates the short window of timeduring which immune responses must be mounted in order to prevent viral infection.
  • Haigwood NL, Zolla-Pazner S. Humoral immunity to HIV, SW and SHIV. AIDS12 (Suppl. A), s121-132 (1998).
  • Burton DR Antibodies, viruses and vaccines. Nature Rev Immunol 2,706–713(2002).
  • Poignard P, Sabbe R, Picchio GR et al Neutralizing antibodies have limited effects on the control of established HIV infection in viva Immunity10,431–438 (1999).
  • Moore JP, Parren PW, Burton BR. Genetic subtypes, humoral immunity and HIV-1 vaccine development. j Viral. 75, 5721–5729 (2001).
  • Moulard M, Phogat SK, She Y et al Broadly cross-reactive HIV-1 neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Prix. Nat! Acad. Li USA 99,6913–6918 (2002).
  • Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR, Koup RA. Passive immunization with human monoclonal antibody protects hu-PBL-SCID mice against challenge by a primary isolate of HIV-1. Nature Ned. 3,1389–1393 (1997).
  • Mascola JR, Stiegler G, VanCott TC et al Protection of macaques against vaginal transmission of a pathogenic HIV/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Med. 6, 207–210 (2000).
  • •One of several reports demonstrating the protective efficacy of neutralizing antibodies, here against mucosal infection.
  • Letvin NL, Walker BD. Immunopathogenesis and immunotherapy in AIDS virus infections. Nature Med. 9, 861–866 (2003).
  • Gorny MK, Williams C, Volsky B et al Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus Type 1 primary isolates from various clades. j Viral. 76,9035–9045 (2002).
  • Sharon M, Kessler N, Levy R, Zolla-Pazner S, Gorlach M, Anglister J. Alternative conformations of HIV-1 V3 loops mimic hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure 11,225–236 (2003).
  • Barnett SW, Lu S, Srivastava I et al The ability of an oliogmeric human immunodeficiency virus Type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. j Viral. 75, 5526–5540 (2001).
  • Srivastava IK, VanDorsten K, Vojtech L, Barnett SW Stamatatos L. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. j Viral. 77 (4), 2310–2320 (2003).
  • Chan DC, Kim PS. HIV entry and its inhibition. Ce1193, 681–684 (1998).
  • Golding H, Zaitseva M, de Rosny E et al Dissection of human immunodeficiency virus Type 1 entry with neutralizing antibodies to gp41 fusion intermediates. Viral. 76,6780–6790 (2002).
  • Gorny MK, Zolla-Pazner S. Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus Type 1 gp41.1 Viral. 74,6186-6192 (2000).
  • Fouts T, Godfrey K, Bobb K et al Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc. Natl Acad. Sc]. USA 99, 11842–11847 (2002).
  • Martin L, Stricher F, Misse D et al. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nature Biotech. 21,71–76 (2003).
  • Hammonds J, Chen X, Ding L et al Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core. Virology314, 636–649 (2003).
  • Grundner C, Mirzabekov T, Sodroski J, Wyatt R. Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins. j Viral. 76, 3511–3521 (2002).
  • Kozlowski PA, Neutra MR The role of mucosal immunity in prevention of HIV transmission. CUI7: Mal Med. 3,217-228 (2003).
  • Mestecky J, McGee JR. Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Acv hnmunol 40,253–245 (1987).
  • Devito C, Hinkula J, Kaul R et al Cross- clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. I Acquir. Immune. Defic. Syndr. 30,413-420 (2002).
  • Clerici M, Barassi C, Devito C. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS16, 1731–1741 (2003).
  • Wright PF, Kozlowski PA, Rybczyk GK. Detection of mucosal antibodies in HIV Type 1-infected individuals. AIDS Res. Hum. Retroviruses 18,1291–1300 (2002).
  • Brandtzaeg P, Farstad IN. In: Mucosa' Immunology Second Edition. Ogra PL, Mestecky J, Lamm ME, Strober W Bienstock J, McGee JR (Eds), Academic Press, CA, USA, 439–468 (1999).
  • Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MBA. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus Type 1 infection. Viral. 68,6103-6110 (1994).
  • Koup RA, Safrit JT, Cao Y et al Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus Type 1 syndrome. j Vim'. 68,4650–4655 (1994).
  • Jin X, Bauer DE, Tuttleton SE et al Dramatic rise in plasma viremia after CD8*T-cell depletion in simian immunodeficiency virus-infected macaques. j Exp. Med. 189, 991–998 (1999).
  • Schmitz JE, Kuroda MJ, Santra S et aL Control of viremia in simian immunodeficiency virus infection by CD8* lymphocytes. Science 283, 857–860 (1999).
  • Goulder PJ, Brander C, Annamalai K. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific T-lymphocyte responses in infected African and Caucasoid adults and children. j Viral 74, 5679–5690 (2000).
  • Ogg GS, Jin X, Bonhoeffer S. Quantitation of HIV-specific cytotoxic T-lymphocytes and plasma load of viral RNA. Science 279, 2103–2106 (1998).
  • Shiver JW, Fu TM, Chen L et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency virus immunity. Nature 415, 331–335 (2002).
  • •Demonstrates the ability of a vaccine designed to elicit Gag cellular immune responses without anti-Env responses, to decrease viremia following exposure and protect against viral-induced disease.
  • Feinberg MB, Moore JP. AIDS vaccine models: challenging challenge viruses. Nature Merl. 8, 207–210 (2002).
  • Barouch DH, Kunstman J, Kuroda MJ etal. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T-lymphocytes. Nature 415, 335–339 (2002).
  • •Reports that viral-specific en responses also elicit selective pressure leading to immune escape.
  • Barouch DH, Kunstman J, Glowczwskie J et al Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T-lymphocytes in DNA-vaccinated rhesus monkeys. j Viral. 77, 7367–7375 (2003).
  • Patterson LI Malkevitch Pinczewski, N. J et al Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-Simian immunodeficiency virus (SW) env/mr, gag and/or nefvaccines and boosted with SW gpl2O.J Viral 77, 8607–8620 (2003).
  • Faneles-Belasio E, Cafaro A, Cara A et al. HIV-1 tat-based vaccines: from basic science to clinical trials. DNA Cell Biol. 21, 599–610 (2002).
  • Betts MR, Yusim K, Koup RA. Optimal antigens for HIV vaccine based on CD8* T response, protein length and sequence variability. DNA Cell Biol. 21, 665–670 (2002).
  • Cafaro A, Caputo A, Fracasso C. Control of SHIV-89.9.P infection in cynomologous monkeys by HIV-1 Tat protein vaccine. Nature Merl. 5, 643–650 (1999).
  • Allen TM, O'Connor DH, Jing P et al. Tat-specific cytotoxic T-lymphocytes select for SW escape variants during resolution of primary viremia. Nature 407, 386–390 (2000).
  • Addo MM, Yu XG, Rosenberg ES, Walker BD, Altfeld M. Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection. DNA Cell Biol. 21, 671–678 (2002).
  • Patterson LJ, Malkevitch NV, Venzon D et al Protection against mucosal SIVmac251 challenge using replicating adenovirus-SIV multi-gene vaccine priming and subunit boosting. j Viral 78, 2212–2221 (2004).
  • ••Reports strong vaccine-induced protectionagainst a virulent, pathogenic SW isolate using the immunization regimen advocated here: priming with a replicating vector (in this case replication-competent Ad) and boosting with envelope subunit proteins.
  • Thomsen AR, Nansen A, Christensen JP, Andreason SO, Marker O. CD40 ligand is pivotal to efficient control of virus replication in mice infected with lymphocytic choriomeningitis virus. Immunal 161, 4583–4590 (1998).
  • Livingstone AM, Kuhn M. Dendritic cells need T-cell help to prime cytotoxic T-cell responses to strong antigens. Eur Immunal 29, 2826–2834 (1999).
  • Oxenius A, Price DA, Easterbrook PJ et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8* and CD4* T-lymphocytes. Proc. Nati Acad. Sci. USA 97, 3382–3387 (2000).
  • Abdelwahad SF, Cocchi F, Bagley KC et al HIV-1-supressive factors are secreted by CD4* T-cells during primary immune responses. Proc. Nati Acad. Sci. USA 100 (25), 15006–15010 (2003).
  • Altes HK, Wodarz D, Jansen VA. The dual role of CD4 T-helper cells in the infection dynamics of HIV and their importance for vaccination. j Theor. Biol. 214, 633–6467 (2002).
  • Ourmanov I, Brown CR, Moss B et al Comparative efficacy of recombinant modified vaccinia Ankara expressing simian immunodeficiency virus (SW) Gag-Pol and/or Env in macaques challenged with pathogenic SI V. I Viral 74, 2740–2751 (2000).
  • Seth A, Ourmanov I, Schmitz JE et al Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SW challenge. Viral. 74, 2502–2509 (2000).
  • Barouch DH, Santra S, Kuroda MJ et al Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. j Viral 75, 5151–5158 (2001).
  • Amara RR, Villinger F, Altman JD et al Control of mucosal challenge and prevention of AIDS by multi-protein DNA/MVA vaccine. Science 292, 69–74 (2001).
  • Vazquez-Blomquist D, Quintana D, Duarte CA. Modified vaccinia virus Ankara (NIVA) priming and fowlpox virus booster elicit stronger CD8+ T-cell response in mice against an HIV-1 epitope than DNA-poxvirus prime-booster approach. Biotechnol. App!. Biochem. Epub ahead of print (2003).
  • Pal R, Venzon D, Letvin NU et al ALVAC- SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. j Viral. 76, 292–302 (2002).
  • Hel Z, Nacsa J, Tryniszewska E et al Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and post-challenge CD4+ and CD8+ T-cell responses. j Immund 169, 4778–4787 (2002).
  • De Bruyn G, Rossini AJ, Chiu Y-L et al Safety profile of recombinant canarypox HIV vaccines. Vaccine 22, 704–713 (2004).
  • Casimiro DR, Chen L, Fu T-M et al Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus and replication-defective adenovirus vectors expressing a human immunodeficiency virus Type 1 gag gene. Viral. 77, 6305–6313 (2003).
  • Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SW vaccine with a deletion in the nef gene. Science 258, 1938–1941 (1992).
  • Baba TW, Liska V, Khinami AH et al Live attenuated multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nature Med. 5, 194–203 (1999).
  • Gundlach BR, Lewis MG, Sopper S et al Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain. j Viral 74, 3537–3542 (2000).
  • Temin HM. A proposal for a new approach to a preventive vaccine against human immunodeficiency virus Type 1. Pmc. Natl. Acad. Sc]. USA 90,4419–4420 (1993).
  • Johnson RP, Lifson JD, Czajak Sc et al Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J. Viral. 73,4952–4961 (1999).
  • Blancou P, Chenciner N, Fang, RHF et al. Simian immunodeficiency virus promoter exchange results in a highly attenuated strain that protects against undoned challenge virus. J. Vim!. 78,1080–1092 (2004).
  • Berkhout B, Verhoef K, Marzio G et al. Conditional virus replication as an approach to a safe live attenuated human immunodeficiency virus vaccine. J. Neurovirol 8 (supp1.2), 134–137 (2002).
  • Gomez-Roman VR, Robert-Guroff M. Adenoviruses as vectors for HIV vaccines. AIDS Rev5,178–185 (2003).
  • Gaydos C, Gaydos J. Adenovirus vaccines in the US military. MI. Med 160,300–304 (1995).
  • Malkevitch N, Patterson LJ, Aldrich K, Richardson E, Alvord WG, Robert-Guroff M. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SW-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques. J. Immunol 170, 4281–4289 (2003).
  • Voltan R, Robert-Guroff M. Live recombinant vectors for AIDS vaccine development. Curl: Mal. Med. 3,273–284 (2003).
  • Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Ce11106, 539–549 (2001).
  • Crotty S, Miller CJ, Lohman BL et al. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J. Vim!. 75,7435–7452 (2001).
  • Murphy CG, Lucas WT, Means RE et al Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J. Vim!. 74, 7745–7754 (2000).
  • Davis NU, West A, Reap E et al Alphavirus replicon particles as candidate HIV vaccine. IUBMB Life 53,209–211 (2002).
  • Takeda A, Igarashi H, Nakamura H et al Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model. J. Viral. 77, 9710–9715 (2003).
  • Gherardi MM, Najera JL, Perez-Jimenez E, Guerra S, Garcia-Sastre A, Esteban M. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. J. VinoI. 77, 7048–7057 (2003).
  • Buge SL, Ma H-L, Amara RR et al. Gp120- alum boosting of a gag-pol-env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge. AIDS Res. Hum. Retroviruses 19,891–900 (2003).
  • Ahlers JD, Belyakov IM, Berzofsky JA. Cytokine, chemokine and costimulatory molecule modulation to enhance efficacy of HIV vaccines. CLI17: Mol. Med. 3,285-301 (2003).
  • Tritel M., Stoddard AM, Flynn BJ et al Prime—boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J. Immunol 171,2538–2547 (2003).
  • Pope M. Dendritic cells as a conduit to improve HIV vaccines. CLI17: Mol. Med 3, 229–242 (2003).
  • Liu LJ, Watabe S, Yang J. et al Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses. Vaccine 20,42–48 (2001).
  • Prlic M, Lefrancois L, Jameson SC. Multiple choices: regulation of memory CD8 T-cell generation and homeostasis by interleukin (IL)-7 and IL-15. I Exp. Med. 195, F49-52 (2002).
  • Lemiale F, Kong W, Akyurek LM etal. Enhanced mucosal immunoglobulin A response of intranasal adenovirus vector human immunodeficiency virus vaccine and localization in the central nervous system. J. Viral. 77,10078–10087 (2003).
  • Lubeck MD, Natuk RJ, Myagkikh M etal. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nattily Med 3,651–658 (1997).
  • Vajdi M, Gardner J, Neidleman J et al Human immunodeficiency virus Type 1 Gag-specific vaginal immunity and protection after local immunizations with Sindbis virus-based replicon particles. I Infer Dis. 184, 1613–1616 (2001).
  • Perri S, Greer CE, Thudium K et al An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and Sindbis viruses is a potent gene-based vaccine delivery vector. J. Viral. 77, 10394–10403 (2003).
  • Lorin C, Mollet L, Delebecque F et al. A single infection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) Type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. Vim'. 78,146–157 (2004).
  • Hanke T, Barnfield C, Wee EGT et al Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J. Gen. Viral. 84,361–368 (2003).
  • Foley HD, Otero M, Orenstein JM, Pomerantz RJ, Schnell MJ. Rhabdovirus-based vectors with human immunodeficiency virus Type 1 (HIV-1 envelopes display HIV-1-like tropism and target human dendritic cells. J. Viral. 76, 19–31 (2002).
  • McGettigan JP, Pomerantz RJ, Siler CA et al. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus Type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J. Viral. 77,237-244 (2003).
  • Xin KQ, Ooki T, Mizukami H et al Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. Hum. Gene Ther. 13,1571–1581 (2002).
  • Ferko B, Katinger D, Grassauer A et al. Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus Type 1 in the genital tract. J. Infer Dis. 178,1359-1368 (1998).
  • Ferko B, Stasakova J, Sereinig S et al. Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus Type 1 nef-specific systemic and mucosal immune responses in mice. J. Viral. 75,8899-8908 (2001).
  • Kawahara M, Matsuo K, Nakasone T et aL Combined intrarectal/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette—Guerin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen. Vaccine 21,158–166 (2002).
  • Harvey TJ, Anraku I, Linedale R et al Kunjin virus replicon vectors for human immunodeficiency virus vaccine development. J Viral. 77,7796–7803 (2003).
  • Devico AL, Fouts TR, Shata MT, Kamin- Lewis R, Lewis GK, Hone DM. Development of an oral prime—boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine 20, 1968-1974 (2002).
  • Evans DT, Chen L-M, Gillis J et al Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella Type III secretion antigen delivery system. J Viral. 77, 2400–2409 (2003).
  • Xu F, Hong M, Ulmer JB. Immunogenicity of an HIV-1 gag DNA vaccine carried by attenuated Shigella. Vaccine 21,644–648 (2003).
  • Peters C, Peng X, Douven D, Pan Z-K, Paterson Y. The induction of HIV Gag-specific CD8* T-cells in the spleen and gut-associated lymphoid tissue by parenteral or mucosal immunization with recombinant Listeria monocytogenes HIV Gag. J limnunol 170,5176–5187 (2003).
  • Rayevskaya M, Kushnir N, Frankel FR. Safety and immunogenicity in neonatal mice of a hyperattenuated Listeria vaccine directed against human immunodeficiency virus.j Viral. 76,918–922 (2002).
  • Xin K-Q, Hoshino Y, Toda Y et al Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. B/ooc/102,223–228 (2003).
  • Marusic C, Rizza P, Lattanzi L et al. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus Type 1.1. Viral. 75,8434-8439 (2001).

Websites

  • The Pipeline Project. http://chi.ucsf.edu/vaccines Accessed July 2004.
  • IAVI Database of AIDS Vaccines in Human Trials. www.iavi.org/trialsdb. Accessed July 2004.
  • Vaxgen announces initial results of its Phase III AIDS vaccine trial. 2-24-2003. Vaxgen announces results of its Phase III HIV vaccine trial in Thailand: Vaccine fails to meet end points. 11-12-2003. www.vaxgen.com/pressroom/index.html Accessed July 2004.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.